Spero Therapeutics Q1 revenue drops on decreased clinical activity

Spero Therapeutics

13/05/2026 21:24

Overview

US biopharma firm's Q1 revenue fell sharply yr/yr after early end of Phase 3 trial

Q1 net loss narrowed yr/yr on lower R&D and administrative expenses

Outlook

FDA review of tebipenem HBr NDA ongoing, with PDUFA date set for June 18, 2026

Spero maintains its cash runway guidance into 2028

Company exploring opportunities to grow its portfolio of clinical-stage product candidates

Result Drivers

LOWER R&D SPENDING - Decreased research and development expenses due to early end of pivotal Phase 3 trial for tebipenem HBr and reduced personnel costs

LOWER ADMINISTRATIVE COSTS - General and administrative expenses declined due to reduced legal and personnel-related costs

REVENUE DECLINE - Revenue fell as a result of lower collaboration and grant revenue following the completion of major clinical milestones

Company press release: ID:nGNX6gPHJZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$7.20 mln
Q1 Income From Operation
-$7.54 mln
Q1 Operating Expenses
$7.80 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Spero Therapeutics Inc is $4.00, about 57.5% above its May 12 closing price of $2.54

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 3 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)